CURRICULUM VITAE

CURRICULUM VITAE

Sung Won Choi, M.D. M.S.

Edith S. Briskin / Shirley K. Schlafer Foundation Research Professor of Pediatrics

Associate Professor of Pediatrics with Tenure

Blood and Marrow Transplantation Program

Department of Pediatrics and Communicable Diseases

300 North Ingalls Building

Room 1101

Ann Arbor, MI 48109

734-764-2774

sungchoi@med.umich.edu

EDUCATION AND TRAINING

Education

09/1988 – 12/1992 B.S., University of Michigan, Literature, Science, and Arts

08/1995 – 06/1999 M.D., Wayne State University, School of Medicine

10/2011 – 05/2013 M.S. University of Michigan, School of Public Health

Training

07/1999 – 06/2000 Intern in Pediatrics, New York University

07/2000 – 06/2001 Junior Resident in Pediatrics, New York University

07/2001 – 06/2002 Senior Resident in Pediatrics, New York University

07/2002 – 06/2003 Clinical Fellow in Pediatric Hematology Oncology, Pediatric and Communicable Diseases, University of Michigan

07/2003 – 06/2006 Post-Doctoral Fellow in Pediatric Hematology Oncology, Blood and Marrow Transplantation Program, Pediatric and Communicable Diseases, University of Michigan

CERTIFICATION AND LICENSURE

Certifications

2002 – 2009 American Board of Pediatrics

2006 – Present American Board of Pediatrics - Pediatric Hematology-Oncology

Licenses

2001 – 2003 State of New York Medical License

2001 – Present State of Michigan Medical License

2002 – Present State of Michigan DEA License

2002 – Present State of Michigan Controlled Substance License

2005 – Present State of Ohio Medical License

2007 – Present State of Ohio DEA License

ACADEMIC AND CLINICAL APPOINTMENTS

Jul 2005 – Oct 2006 Clinical Lecturer, Division of Pediatric Hematology Oncology, Blood and Marrow Transplant Program, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center

Nov 2006 – Mar 2011 Clinical Track Assistant Professor, Division of Pediatric Hematology Oncology, Blood and Marrow Transplant Program, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center

Apr 2011 – August 2016 Instructional (Tenure) Track Assistant Professor, Division of Pediatric Hematology Oncology, Blood and Marrow Transplant Program, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center

Sept 2016 Associate Professor with Tenure, Division of Pediatric Hematology Oncology, Blood and Marrow Transplant Program, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center

RESEARCH INTERESTS

1. Translation of novel therapeutics for the prevention of acute graft versus host disease (GVHD) from the laboratory to the clinic.

2. Correlate human blood samples with clinical outcomes in the setting of investigator-initiated clinical HCT trials to better understand the biology.

3. Develop hypothesis-generated clinical trials that seek to improve the efficacy of clinical HCT (e.g. utilizing databases and health information technology tools).

GRANTS

Present and Active

Sponsor: NIH/AHRQ – R21 HS23613

Role: Principal Investigator

Title: Personalized Engagement Tool for Pediatric BMT Patients and Caregivers

Total Project Period: 09/01/14 – 02/28/17

Total Direct Costs: $200,501

Effort: calendar

Sponsor: NIH/NCI – R21 CA198776

Role: Principal Investigator

Title: Vorinostat for GVHD Prevention in Myeloablative Conditioning Unrelated Donor Transplant

Total Project Period: 07/01/15 – 06/30/17

Total Direct Costs: $275,000

Effort: calendar

Sponsor: Gateway for Cancer Research

Role: Principal Investigator

Title: Neurocognitive Function and Quality of Life after Vorinostat for GVHD Prevention

Total Project Period: 12/01/14 – 11/30/17

Total Direct Costs: $526,351

Effort: 2.4 calendar

Sponsor: Brian Parker Foundation

Role Principal Investigator

Title: Improving clinical outcomes after GVHD

Total Project Period: 12/01/16 – 11/30/17

Total Direct Costs: $20,000

Effort: 0.0 Calendar

Sponsor: A. Alfred Taubman Medical Research Institute, Emerging Scholar

Role Principal Investigator

Title: Development of a novel therapy for prevention of GVHD

Total Project Period: 01/01/12 – 12/31/17

Total Direct Costs: $200,000

Effort: 0.0 Calendar

Sponsor: Bristol Myers Squibb

Role Principal Investigator

Title: The SMART CART Study

Total Project Period: 12/01/16 – 11/30/2019

Total Direct Costs: $150,000

Effort: 0.0 Calendar

Sponsor: Grand Challenge Award

Role Principal Investigator

Title: Individualized Disease Prediction using a Multi-Dimensional, Time-Resolved "Big Data" Approach

Total Project Period: 07/01/17 – 06/30/18

Total Direct Costs: $200,000

Effort: 0.0 Calendar

Previous Grants

Sponsor: Hyundai Hope On Wheels

Role: Principal Investigator

Title: Impact of obesity in allogeneic hematopoietic stem cell transplantation

Total Project Period: 07/01/14 – 06/31/16

Total Direct Costs: $137,500

Effort: 1.2 calendar

Sponsor: Gracie's Leukemia Fund

Role Principal Investigator

Title: Development of a novel health information tool for Pediatric BMT

Total Project Period: 07/01/15 – 06/31/16

Total Direct Costs: $20,000

Effort: 0.0 Calendar

Sponsor: Charlie Porter Leukemia Fund

Role: Principal Investigator

Title Improving clinical outcomes for GVHD

Total Project Period: 07/01/15 – 06/31/16

Total Direct Costs: $40,000

Effort: 0.0 calendar

Sponsor: NIH/NIAID – K23 Career Development Award, K23 AI-091623-01

Role: Principal Investigator

Title: Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent GVHD

Total Project Period: 01/01/11 – 12/31/15

Total Direct Costs: $657,630

Effort: 6.6 calendar

Sponsor: NIH/NCI – P01 CA039542 (Ferrara, PI)

Role: Co-Investigator

Title: Cellular and Molecular Studies of Bone Marrow Transplant

Total Project Period: 07/01/10 – 08/31/15

Annual Direct Costs: $1,191,623

Effort: 1.2 calendar* *unfunded and concurrent with K23

Sponsor: Fostering Innovations Grant

Role Principal Investigator

Title: Development a novel health information technology platform for use in clinical BMT

Total Project Period: 01/01/13 – 12/31/15

Total Direct Costs: $3,800

Effort: 0.0 Calendar

Sponsor: St. Baldrick's Foundation Scholar Award

Role: Principal Investigator

Title: The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute GVHD

Total Project Period: 07/01/08 – 06/30/13

Total Direct Costs: $560,000

Effort: 0.0 calendar

Sponsor: University of Michigan Comprehensive Cancer Center - Clinical Translational Resource Allocation/Translational Award

Role: Principal Investigator

Title: UMCC 2007.139 (HUM 00017897) – Phase 2 clinical trial for Early Skin Acute Graft-Versus-Host Disease

Total Project Period: 05/01/08– 07/31/13

Total Direct Costs: $178,911

Effort: 0.0 calendar

Sponsor: Helen L. Kay Charitable Trust – Helen L. Kay Pediatric Cancer Research Award

Role: Principal Investigator

Title: (No Grant Number Assigned) – Plasma cytokines in early Grade I Skin Graft-Versus-Host Disease

Total Project Period: 07/01/08 – 06/30/13

Total Direct Costs: $25,000

Effort: 0.0 calendar

Sponsor: Nancy Newton Loeb Fund – Nancy Newton Loeb Pediatric Cancer Research Award

Role: Principal Investigator

Title: (No Grant Number Assigned) – Mechanisms of chemokine trafficking in acute GVHD

Total Project Period: 01/01/06 – 06/30/11

Total Direct Costs: $10,000

Effort: 0.0 calendar

Sponsor: Woodson Biostatistics Fund Award

Role: Principal Investigator

Title: Epidemiology of central line associated bloodstream infections in pediatric BMT patients

Total Project Period: 07/01/12 – 06/31/13

Annual Direct Costs: $1,000

Effort: 0.0 calendar

Sponsor: Alex's Lemonade Stand Foundation

Role: Principal Investigator

Title: Development of a Diagnostic Test for GVHD

Total Project Period: 07/01/06 – 06/30/08

Total Costs: $60,000

Mentor: Kenneth R. Cooke

HONORS AND AWARDS

2004 Basic Science Fellow Award in the Department of Pediatrics and Communicable Diseases, University of Michigan Health Center

2005 Nancy Newton Loeb Pediatric Cancer Research Grant Recipient

2006 Alex's Lemonade Stand Foundation Grant Recipient

2006 Hope Street Kids Grant Recipient

2008 Helen L. Kay Cancer Research Grant Recipient

2008 St. Baldrick's Scholar Award Recipient

2012 Woodson Biostatistics Fund Award Recipient

2012 Charlie Porter Foundation Award

2012 Best of ASH (selected oral abstract)

2013 A. Alfred Taubman Research Institute Emerging Scholar

2013 ASBMT Best Abstract Award for outstanding basic science research

2013 Fostering Innovations Grant Award Recipient

2014 Gracie's Fund Leukemia Research Award Recipient

2014 Hope On Wheels Award Recipient

2016 TAMS (Token of Appreciation from Medical Students) Award

2016 Edith S. Briskin and Shirley K. Schlafer Foundation Research Professor of Pediatrics

2016 Best Abstract (BMT Roadmap Project) at the Center for Healthcare Engineering and Patient Safety Annual Symposium

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

2002 – Present American Society of Hematology

2003 – Present American Society for Blood and Marrow Transplantation

2006 – Present American Society of Pediatric Hematology/Oncology

2007 – 2010 American Association for Cancer Research

2010 – Present Central Society for Clinical and Translational Research

2010 – Present Pediatric Blood and Marrow Transplantation Consortium

2016 – Present American Society of Clinical Oncology

PEER-REVIEW SERVICE

2008 – Present Blood and Bone Marrow Transplantation

2008 – Present Bone Marrow Transplantation

2011 – Present Transplantation

2011 – Present Cell Transplantation

2014 – Present Haematologica

2014 – Present Blood

2016 – Present Pediatric Transplantation

2016 – Present Applied Clinical Informatics

2016 – Present International Journal of Medical Informatics

2016 – Present Cancer Medicine

TEACHING

Please see Educator's Portfolio for full details

Mentees

Undergraduate students

Name: Shuang (George) Zhao, M.D., Ph.D.

Current Position Radiation Oncology Resident, University of Michigan

Name: Tianyi Wang

Current Position: Medical Student, University of Michigan, M.D., class of 2017

Name: Alex Fauer

Current Position: PhD Candidate, University of Michigan School of Nursing

Name: Anna Munaco

Current Position: MD Candidate, class of 2021

Name: Roshun Sankaran

Current Position: MD Candidate, class of 2021

Graduate students

Name: Lawrence Chang, M.D., M.P.H., M.H.I.

Current Position: Pfizer (Indianapolis, IN)

Name: Jodyn Platt, Ph.D.

Current Position: Faculty, Learning Health Sciences, University of Michigan

Name: Ayse Buyuktur, Ph.D.

Current Position: Postdoctoral Fellow, School of Information, University of Michigan

Name: Elizabeth Kaziunas

Current Position: Graduate student, School of Information, University of Michigan, Ph.D. candidate, class of 2017

Name: Molly Maher, MHI

Current Position: Emerging Solutions Analyst at Michigan Health Information Network Shared Services

Name: Mohamad Baydoun

Current Position: PhD Candidate, School of Nursing

Medical students

Name: Rohini Rao, M.D.

Current Position: Physical Medicine and Rehabilitation Resident, Vanderbilt University

Name: Michael Gleimer, Ph.D.

Current Position: Medical Student, University of Michigan, M.D. candidate, class of 2017

Name: Yeohan Song, M.D.

Current Position: Internal Medicine Resident, Wayne State University

Name: Komal Chughtai, M.D.

Current Position: Radiology Resident, University of Rochester

Name: Rahael Gupta, B.A., M.S.

Current Position: Medical Student, University of Michigan, M.D. candidate, class of 2018

Resident

Name: Hemasri Tokala M.D.

Current Position: Hematology-Oncology fellow, Michigan State University

Fellow

Name: Holly Miller, D.O.

Current Position: Assistant Professor, Phoenix Children's Hospital

Name: Lyndsey Runnas M.D.

Current Position: Hematology-Oncology fellow, University of Michigan

COMMITTEE AND ORGANIZATIONAL SERVICE

Institutional Committees

2006 – 2011 Quality Management Officer, Blood and Marrow Transplantation Program

2006 – 2008 Clinical Practice Guidelines Officer, Blood and Marrow Transplantation Program

2007 – 2016 Physician Lead, Oncology/BMT Catheter Practice Procedures Working Committee

2008 – 2013 Acute GVHD Faculty Continuity Grader

2010 – 2013 Member, Department of Pediatrics Research Advisory Committee

National Committees

2008, 2014 Member, Pediatric Blood and Marrow Transplant Consortium Acute GVHD Working Group

2008 – 2014 Member, Bone Marrow Transplant Clinical Trials Network (Protocol 0402) Protocol Team

2016 – 2017 Pediatric Blood and Marrow Transplant Consortium Annual Meeting Planning Committee

2016 – 2017 Track Leader for Pediatric Oncology, ASCO Cancer Education Committee

2016 Moderator, Gateway for Cancer Research Scientific Symposium

2016 Pediatric Blood and Marrow Transplant Consortium, Support Care Committee, Co-Chair

2016 American Society of Clinical Oncology (Education Committee, Track Leader)

2016 Blood and Marrow Transplant Clinical Trials Network (Special Populations Committee Member)

EXTRAMURAL INVITED PRESENTATIONS

Regional

Jun 2005 "Graft-versus-Host Disease: from the clinic to the bench and back again," Pediatric Grand Rounds, Hurley Medical Center, Flint, MI.

Mar 2009 "Childhood Cancer," St. Baldrick's Foundation Fundraiser for Childhood Cancer, Livonia, MI.

May 2009 "Quality systems applications in clinical transplantation," 36^th Annual Current Topics in Blood Banking Conference, Department of Pathology, University of Michigan Medical School, Kensington Court, Ann Arbor, MI.

Mar 2010 "Childhood Cancer," St. Baldrick's Foundation Fundraiser for Childhood Cancer, Ann Arbor, MI.

Mar 2011 "Childhood Cancer," St. Baldrick's Foundation Fundraiser for Childhood Cancer, Ann Arbor, MI.

Mar 2012 "Childhood Cancer," St. Baldrick's Foundation Fundraiser for Childhood Cancer, Ann Arbor, MI.

Mar 2013 "Childhood Cancer," St. Baldrick's Foundation Fundraiser for Childhood Cancer, Northville, MI.

Mar 2014 "Childhood Cancer," St. Baldrick's Foundation Fundraiser for Childhood Cancer, Northville, MI.

Apr 2014 "Histone deacetylase inhibition for GVHD prevention," A. Alfred Taubman Emerging Scholar Program, Inaugural Research Symposium, University of Michigan, Basic Science Research Building, Ann Arbor, MI.

April 2016 "Graft-versus-host disease prevention in hematopoietic cell transplantation," A. Alfred Taubman Emerging Scholar Program Scientific Symposium, University of Michigan, Basic Science Research Building, Ann Arbor, MI.

May 2016 "Childhood Cancer," St. Baldrick's Foundation Fundraiser for Childhood Cancer, Plymouths, MI.

May 2017 "Post-transplant Lymphoproliferative Disease," Nursing Conference, Ann Arbor, MI

National

May 2006 "Role of CCR1:CCL5 (Rantes) receptor ligand interactions in modulating allogeneic T cell responses following stem cell transplantation," Northwestern Children's Memorial Hospital, Chicago, IL.

Feb 2008 "Novel strategy for early skin GVHD," Stanford Children's Hospital, Blood and Marrow Transplantation Program, Stanford, CA.

Jul 2008 "The use of etanercept as sole treatment for grade 1 acute graft versus host disease," American Society for Blood and Marrow Transplantation, Clinical Research Training Course, Park City, UT.

Aug 2008 "The use of etanercept as treatment for acute graft-versus-host disease," Columbia University Children's Memorial Hospital, New York, NY

Dec 2009 "Standard GVHD prophylaxis augmented with TNF-inhibition in alternative donor HCT: lower TNFR1 levels correlate with better outcomes," American Society of Hematology, New Orleans, LA.

Feb 2010 "TNF-inhibition with etanercept for GVHD prevention in alternative donor HCT: lower TNFR1 levels correlate with better outcomes," American Society of Blood and Marrow Transplantation, Orlando, FL.

Oct 2011 "Targeting histone deacetylases for prevention of GVHD," Leukemia and Lymphoma Society, Translational Research Program, New York City, NY.

Sept 2012 "A Phase 1/2 clinical trial of vorinostat for GVHD prevention," Pediatric Hematology Oncology Grand Rounds, Indiana University, Indianapolis, IN.

Dec 2012 "Targeting histone deacetylases as a new strategy for prevention of GVHD," American Society of Hematology, Atlanta, GA.

Feb 2013 "Targeting deacetylases as a novel strategy for prevention of acute GVHD," American Society of Blood and Marrow Transplantation, Salt Lake City, UT.

Sep 2014 "Alpha-1-antitrypsin in steroid refractory acute GVHD," Pediatric Blood and Marrow Transplant Consortium, Dallas, TX.

May 2016 "Applying Research to Clinical Practice and Clinical Practice to Research," Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.

May 2016 "Safer Health Across the Continuum of Care," University of Alabama Children's Hospital, Birmingham, AL.

May 2016 "How to Write a Successful Grant," Pediatric Blood and Marrow Transplant Consortium, Minneapolis, MN.

Oct 2016 "Vorinostat to Prevent GVHD – Phase II Clinical Trial," The Chicago Chronic GVHD Meeting, Chicago, IL.

Feb 2017 "Acute GVHD" American Society of Blood and Marrow Transplantation, Orlando, FL.

International

Feb 2017 "GVHD History, Pathophysiology, and Management," McGill University Human Genetics Students; Society Conference, Montreal, Quebec.

Mar 2017 "GVHD in HSCT: Emerging Therapies for Refractory Disease," European Blood and Marrow Transplantation Meeting, Marseille, France

April 2017 Plenary Session Chair, "Novel Approaches to Juvenile Myelomonocytic Leukemia (JMML)," PBMTC/ASPHO, Montreal, Quebec

BIBLIOGRAPHY

1. Choi SW, Bangaru BS, Wu CD, Finlay JL. Gastrointestinal involvement in disseminated LCH with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine. J Pediatr Hematol Oncol 2003, 25:503-506.

2. Hildebrandt GC, Olkiewicz KM, Choi S, Corrion LA, Clouthier SG, Liu C, Serody JS, Cooke KR. Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. Blood 2005, 105:2249-2257.

3. Choi SW, Boxer LA, Pulsipher M, Roulston D, Hutchinson R, Yanik G, Cooke KR, Ferrara JLM, Levine JE. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant 2005, 35:473-477.

4. Choi SW, Wechsler DS. Burkitt lymphoma in a child with osteogenesis imperfecta. Pediatr Blood Cancer 2005, 45:863-864.

5. Choi SW, Islam S, Yanik G, Levine JE, Hutchinson RJ, Ferrara JLM, Greenson JK, Cooke KR. The use of laparoscopic liver biopsies in pediatric patients with hepatic dysfunction following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:891-896.

6. Choi SW, Hildebrandt GC, Olkiewicz KO, Hanauer DA, Silva IA, Chaudhary M, Fisher J, Vannella K, Chensue SW, Liu C, Cooke KR. CCR1:CCL5 (RANTES) receptor ligand interactions modulates allogeneic T cell responses and reduces graft-vs-host disease following stem cell transplantation. Blood 2007, 110:3447-3455. PMCID:PMC2200916.

7. Hildebrandt GC, Choi SW, Mueller G, Olkiewicz KM, Moore BB, Cooke KR. The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation. Pediatr Blood Cancer 2008, 50(4):911-14.

8. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JL. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111(4):2470-5. PMCID: PMC2361693.

9. Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S, Krijanovski O, Jones D, Whitfield J, Cooke K, Hutchinson RJ, Ferrara JL, Levine JE. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008, 112(4):1539-42. PMCID: PMC2515125.

10. Kitko CL, Paczesny S, Yanik G, Braun T, Jones D, Whitfield J, Choi SW, Hutchinson RJ, Ferrara JL, Levine JE. Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. Biol Blood Marrow Transplant 2008, 14(7):759-65. PMCID: PMC2577819.

11. Hanauer DA, Choi SW. Re: "Risk of childhood leukemia associated with vaccination, infection, and medication use in childhood: the Cross-Canada Childhood Leukemia Study". Am J Epidemiol 2008, 168(3):353.

12. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008, 112(12):4425-31. PMCID: PMC2597119.

13. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek DE, Cooke KR, Kitko CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine JE, Hanash SM, Ferrara JL. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113(2):273-8. PMCID: PMC2615645.

14. Paczesny S, Choi SW, Ferrara JL. Acute graft-versus-host disease: New treatment strategies. Curr Opin Hematol 2009, 16(6): 427-36. PMCID: PMC4141413.

15. Choi S, Reddy P. Graft-versus-host disease. British Medical Journal Point of Care 2009, 2010, 2011, 2012, 2013, 2014. Epocrates Online, British Medical Journal.

16. Choi SW, Levine JE, Ferrara JLM. Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 2010, 30(1): 75-101. PMCID: PMC4141413.

17. PaczesnyS, Braun TM, Levine JE, HoganJ, CrawfordJ, CoffingB, Olsen^,S, ChoiSW, WangH, FacaV, PitteriS, ZhangQ, ChinA, KitkoC, MineishiS, YanikG, PeresE, HanauerD, WangY, ReddyP, Hanash S, and FerraraJLM. Elafin is a biomarker of graft versus host disease of the skin. Sci Transl Med 2010, 2(13): 13ra2. PMCID: PMC2895410.

18. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, Bickley D, Braun TM, Jang PS, Lowler KP, Jones DM, Choi SW, Reddy P, Mineishi S, Levine JE, Ferrara JL, Paczesny S. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010, 16:907-914. PMCID: PMC2916071.

19. Choi S, Reddy P. Graft-versus-Host Disease. Panminerva Medica 2010, 52:111-124. Review.

20. Choi SW, Levine J. Indications for hematopoietic cell transplantation for children with severe congenital neutropenia. Pediatr Transplant 2010, 14(8): 937-9.

21. Silva IA, Olkiewicz K, Askew D, Fisher JM, Chaudhary MN, Vannella KM, Deurloo DT, Choi SW, Pierce EM, Clouthier SG, Liu C, Cooke KR. Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: A shifting paradigm for T cell allo-activation. Biol Blood Marrow Transplant 2010, 16(5):598-611. PMCID: PMC3838892.

22. Choi S, Reddy P. HDAC inhibition and graft versus host disease. Mol Med 2011, 17(5-6): 404-416. PMCID: PMC3105142.

23. Choi S, Reddy P. Donor Tregs suppress the good with the bad after allogeneic BMT. Leuk Res 2011, 35(12):6702-8.

24. Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi SW, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S. Clofarabine and busulfan conditioning facilitates engraftment and provides significant anti-tumor activity in non-remission hematologic malignancies. Blood 2011, 118(15):4258-64.

25. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E, Landfried K, Akashi K, Vander Lugt M, Reddy P, Chin A, Zhang Q, Hanash S, Paczesny S. Regenerating islet-derived 3 alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011, 118(25):6702-8. PMCID: PMC3242723.

26. Connelly JA, Choi SW, Levine JE. Hematopoietic stem cell transplantation for severe congenital neutropenia. Current Opin Hematol 2012, 19(1);44-51. PMCID: PMC3291495.

27. Choi S, Hoffmann S, Cooling L. Another case of acute cardiopulmonary toxicity with cord blood infusion: Is dextran the culprit? Transfusion 2012, 52(1):207-8. PMCID: PMC3433065.

28. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Landfried K, Akashi K, Vander Lugt M, Couriel DR, Reddy PR, Paczesny S. Plasma biomarkers of lower gastrointestinal and liver acute graft versus host disease. Blood 2012, 119(12):2960-3. PMCID: PMC3327467.

29. Choi, SW, Stiff P, Cooke K, Ferrara JLM, Braun T, Kitko C, Reddy P, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE. TNF-inhibition with etanercept for graft versus host disease prevention in high risk HCT: Lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant 2012, 18(10):1525-32. PMCID: PMC3443302.

30. Choi SW, Weizer AZ, Sarma AV. Measures of impact: Diabetes and urothelial cancer. Cancer Epidemiology 2012, 36(6):579-80.

31. Choi SW, Chang L, Hanauer DA, Shaffer-Hartman J, Teitelbaum D, Lewis I, Blackwood A, Akcasu N, Steel J, Christensen J, Niedner MF. Rapid reduction of central line infections in hospitalized pediatric oncology patients through simple quality improvement methods. Pediatr Blood Cancer 2013, 60(2):262-9. PMCID: PMC3720122.

32. Hanauer DA, Zheng K, Commiskey, E, Duck MG, Choi SW, Blayney DW. Computerized prescriber order entry implementation on a physician assistant-managed hematology and oncology inpatient service: Effects on workflow and task switching. Journal of Oncology Practice 2013, 9(4):e103-e14. PMCID: PMC3710176.

33. Harris AC, Kitko CL, Couriel DL, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE. Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica. 2013, 98(2):179-84. PMCID: PMC3561423.

34. Toubai T, Sun Y, Luker G, Liu J, Luker KE, Tawara I, Evers R, Liu C, Matthewson N, Malter C, Nieves E, Choi S, Murphy KM, Reddy P. Host derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood 2013; 121(20):4231-41. PMCID: PMC3656455.

35. Vander Lugt, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Won C, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JLM, Paczesny S. ST2 and therapy-resistant graft-versus-host disease and mortality. NEJM 2013, 369(6):529-39. PMCID: PMC3943357.

36. King EA, Hanauer DA, Choi SW, Jong N, Hamstra DA, Li Y, Farley FA, Caird MS. Osteochondromas after radiation for pediatric malignancies: A role for expanded counseling for skeletal side effects. J Pediatr Orthop 2013, 34(3):331-5. PMCID: PMC33930617.

37. Choi SW, Braun T, Chang L, Ferrara JL, Pawarode P, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P. Phase 1/2 trial of vorinostat plus tacrolimus and mycophenolate to prevent graft versus host disease following related donor reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Lancet Oncol 2014, 15(1):87-95. PMCID: PMC4103793.

38. Hanauer DA, Preib R, Zheng K, Choi SW. Patient-initiated electronic health record amendment requests. J Am Med Inform Assoc. 2014, 21(6):992-1000. PMCID: PMC4215043.

39. Toubai, T, Hou G, Matthewson N, Liu C, Wang Y, Oravecz-Wilson, K, Cummings, E, Rossi C, Evers R, Sun, Y, Wu, J, Choi S, Fang, D, Zheng P, Liu Y, Reddy P. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood 2014, 123(22):3512-23. PMCID: PMC4041170.

40. Chang L, Frame D, Braun T, Gatza E, Hanauer DA, Zhao S, Magenau JM, Schultz K, Tokala H, Ferrara JL, Levine JE, Reddy P, Paczesny S, Choi SW. Engraftment Syndrome following allogeneic hematopoietic cell transplantation predicts poor outcomes. 2014, 20(9):1407-17. PMCID: PMC4142041.

41. Gatza E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DA, Goldstein S, Connelly J, Reddy P, Paczesny S, Choi SW. Etanercept plus topical corticosteroids as initial therapy for grade 1 acute graft-versus-host disease after allogeneic cell transplantation. Biol Blood Marrow Transplant 2014, 20(9):1426-34. PMCID: PMC4145722.

42. Choi SW and Reddy P. Current status and emerging strategies for the prevention of graft-versus-host disease. Nature Reviews Clinical Oncology 2014, 11(9):536-47. PMCID: PMC4151470.

43. Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu J, Waller EK, Grupp S, McCarthy P, Wu J, Hu, Z, Carter SL, Horowitz MM, Antin JH. A randomized, phase 3 trial comparing tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation: results of the BMT CTN 0402 trial. Blood 2014, 124(8):1372-7. PMCID: PMC4141519.

44. Keusch F, Rao R, Chang L, Lepkowski J, Reddy P, Choi SW. Participation in clinical research: perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20(10):1604-11. PMCID: PMC4163094.

45. Abedin S, Levine J, Choi S, Yanik G, Couriel D. Double umbilical cord blood transplantation after novel myeloablative conditioning using FluBu4/TLI. Biol Blood Marrow Transplant 2014, 20(12):2062-6. PMCID: PMC4291068.

46. Kaziunas E, Buyuktur A, Jones J, Choi S, Hanauer D, Ackerman M. Transition and Reflection in the Use of Health Information: The Case of Pediatric Bone Marrow Transplant Caregivers. In: Proceedings of the ACM 2015 Conference on Computer Supported Cooperative Work (CSCW '15).

47. Gleimer M, Li Y, Chang L, Paczesny S, Hanauer DA, Frame DG, Byersdorfer CA, Reddy P, Braun T, Choi SW. Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes. Biol Blood Marrow Transplant 2015; 50(3):402-10. PMCID: PMC4351174.

48. Marini BL, Choi SW, Byersdorfer CA, Cronin S, Frame DG. Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant 2015; 21(5):809-20. PMCID: PMC4408224.

49. Song Y, Bixby D, Roulston D, Magenau, Choi SW. The challenge of t(6;9) and FLT3-positive Acute Myelogenous Leukemia in a young adult. Journal of Leukemia 2014, 2:1000167-1-10. PMCID: PMC4515430.

50. Choi SW, Gatza E, Hou G, Sun Y, Whitfield J, Song Y, Oravecz-Wilson K, Tawara I, Dinarello C, Reddy P. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood 2014, 125(5):815-9. PMCID: PMC4311228.

51. Toubai T, Hou G, Rossi C, Matthewson NM, Oravecz-Wilson K, Cummings E, Wu J, Sun Y, Choi S, Reddy P. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation. OncoImmunology 2015, 4(7):e1016699-1-11. PMCID: PMC4485841.

52. Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol 2015, 94(6):1033-41.

53. Kaziunas E, Hanauer DA, Ackerman M, Choi SW. Identifying unmet information needs in the inpatient setting to increase patient and caregiver engagement in the context of pediatric hematopoietic stem cell transplantation. J Am Med Inform Assoc. 2016; 23(1):94-104. PMCID:PMC5009939.

54. Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer DA, Chughtai K, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplantation 2016; 5(3):446-50. PMCID: PMC4720584.

55. Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR. Reducing treatment-related mortality did not improve outcomes of allogeneic myeloablative hematopoietic cell transplantation for high-risk multiple myeloma: A University of Michigan Prospective Series. Biol Blood Marrow Transplant 2016; 22(1):54-60.

56. Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA 2015; 314(9):913-25. PMCID: PMC4758114.

57. Gatza E and Choi SW. Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. International Journal of Hematology Oncology 2015; 4(3):113-26. PMCID: PMC4863650.

58. Maher M, Hanauer DA, Kaziunas E, Ackerman M, Derry H, Forringer R, Miller K, O'Reilly D, An LC, Tewari M, Choi SW. A pilot study of a novel health information technology communication system to increase caregiver activation in the context of hospital-based pediatric hematopoietic cell transplantation. JMIR Research Protocols 2015;4(4):e119. PMID: PMC4704973.

59. Chughtai K, Song Y, Zhang P, Derstine B, Wang SC, Choi SW. Analytic morphomics: A novel CT imaging approach to quantify adipose tissue and muscle composition in allogeneic HCT. Bone Marrow Transplantation 2016; 5(3):446-50. PMCID: In Process.

60. Maher M, Kaziunas E, Ackerman M, Derry H, Forringer R, Miller K, O'Reilly D, An LC, Tewari M, Hanauer D, Choi SW. User-centered Design Groups to engage patients and caregivers with a personalized health IT tool. Biol Blood Marrow Transplant 2016; 22(2): 349-58. PMCID: PMC4716891.

61. Kitko CL, Braun T, Couriel DR, Choi SW, Goldstein S, Magenau J, Pawarode A, Reddy P, Schuler C, Yanik G, Ferrara J, Levine JE. Combination therapy for GVHD prophylaxis with etanercept and extracorporeal photopheresis: Results of a phase II clinical trial. Biol Blood Marrow Transplant 2016; 22(5):862-8. PMCID: PMC4839477.

62. Platt J, Thiel DB, Kardia SLR, Choi SW. Innovating consent for pediatric HCT patients. Bone Marrow Transplantation 2016; 51(6):885-8. PMCID:PMC4896835.

63. Hanauer DA, Branford GL, Greenberg G, Kileny S, Couper MP, Zheng K, Choi SW. Two-year longitudinal assessment of physicians' perceptions after replacement of a long- standing homegrown electronic health record: Does a J-curve of satisfaction really exist? Journal of the American Medical Informatics Association 2016. Epub ahead of print.

64. Li W, Liu L, Gomez A, Zhang J, Ramadan A, Zhang Q, Choi SW, Zhang P, Greenson JK, Liu C, Jiang D, Virts E, Kelich SL, Chu HW, Flynn R, Blazar BR, Hanenber H, Hanash S, Paczesny S. Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI insight 2016; 1(6). PMCID:PMC4868256.

65. Bouma S, Peterson M, Gatza E, Choi SW. Nutritional status and weakness following pediatric hematopoietic cell transplantation. Pediatric Transplantation 2016; Epub ahead of print.

66. Raj M, Choi SW, Platt J. An exploration of the informed consent process in hematopoietic cell transplantation clinical research and opportunities for improvement. Bone Marrow Transplantation 2016; Epub ahead of print.

67. Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S, Choi SW. Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform clinical and transplant characteristics post-allogeneic hematopoietic cell transplantation. Blood 2016; Epub ahead of print.

68. Miller HK, Braun TM, Stillwell T, Harris AC, Choi SW, Connelly JA, Couriel D, Goldstein S, Kitko CL, Magenau J, Pawarode A, Reddy P, Riwes M, Yanik GA, Levine JE. Infectious risk following allogeneic hematopoietic cell transplant complicated by acute graft-versus-host disease. Biol Blood Marrow Transplant 2016; Epub ahead of print.

69. Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann LE, Yu LC, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Karfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hasmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. GVHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplantation 2016; Epub ahead of print.

70. Cooling L, Mody R, Sankar A, Yanik G, Bonifant C, Choi SW. A severe umbilical cord stem cell infusion reaction due to dextran in an atopic pediatric transplant patient. Accepted, Bone Marrow Transplantation 2017; In Press.

71. Runaas L, Hanauer D, Maher M, Bischoff E, Fauer A, Gupta R, Hoang T, Munaco A, Sankaran R, Seyedsalehi S, Cohn A, An L, Tewari M, Choi SW. BMT Roadmap: A User-Centered Design Health Information Technology Tool to Promote Patient-Centered Care in Pediatric HCT. Accepted, Biol Blood Marrow Transplant 2017; In Press.

72. Cooling L, Hoffmann S, Webb D, Yamada C, Davenport R, Choi SW. Performance and safety of femoral central venous catheters in pediatric autologous peripheral blood stem cell collection. Submitted and under review.

Book Chapters

1. Hanauer DA, Zheng K, Mei Q, Choi SW. Full-Text search in electronic health records: Challenges and opportunities. In: Kutais BG, ed. Internet Policies and Issues. Volume 7. Hauppauge, NY: Nova Science Publishers; 2011:125-140.

2. Choi S, Reddy P. Principles of Hematopoietic Cell Transplantation and GVHD. Transplant Immunology. Eds: Li X and Jevniker A, John Wiley & Sons Ltd, 2014.

Abstracts

1. Choi SW, Devasagayam TPA, Kumashi P, Gore SG, Dutta S, Franko A, Dulchavsky S. Oxidative damage in the hypothermic cardioplegically preserved rat heart. 27^th Annual Michigan Cardiovascular Research Forum, Abstract Oral Session, Ann Arbor, MI, 1997.

2. Choi SW, Devasagayam TPA, Kumashi P, Gore SG, Dutta S, Franko A, Dulchavsky S. Oxidative damage in the hypothermic cardioplegically preserved rat heart. Wayne State University School of Medicine Research Symposium, Abstract Oral Session, Detroit, MI, 1997.

3. Choi SW, Bangaru BS, Wu CD, Finlay JL. Gastrointestinal involvement in disseminated LCH with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine. Digestive Disease Week, Abstract Poster Session, Atlanta, GA, May 2002.

4. Choi SW, Olkiewicz K, Hildebrandt GC, Corrion LA, Liu C, Lowe J, Cooke KC. Role of selectin and selectin ligand receptors in the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. 15^th Annual Pediatric Research Symposium, Department of Pediatrics and Communicable Diseases, University of Michigan, Abstract Oral Session (Fellow Award for Basic Science Research), Ann Arbor, MI, October 2004.

6. Hildebrandt GC, Choi SW, Olkiewicz KM, Chensue SW, Liu C, Cooke KR. CCR1 expression on donor leukocytes is critical to the development of graft versus host disease after allogeneic SCT. American Society of Hematology Annual Meeting, Abstract Poster Session, San Diego, CA, December 2004. Blood 2004 Dec; 104(11):838a, November 2004.

7. Hildebrandt GC, Olkiewicz KM, Choi SW, Corrion LA, Liu C, McKenzie AN, Cooke KR. IL-13 –predictor of or protector from acute graft versus host disease? American Society of Hematology Annual Meeting, Abstract Poster Session, San Diego, CA, December 2004. Blood 2004 Dec; 104(11):839a, November 2004.

8. Choi SW, Hildebrandt GC, Silva IA, Olkiewicz KM, Chensue SW, Liu C, Chaudhary MN, Fisher J, Lane TE, Cooke KR. Critical role for CCR1:CCL5 (RANTES) receptor ligand interactions in modulating allogeneic T cell responses following bone marrow transplantation. American Society of Hematology Annual Meeting, Abstract Poster Session, Atlanta, GA, December 2005. Blood 2005, 106(11): 869a, November 2005.

9. Choi SW, Hildebrandt GC, Silva IA, Olkiewicz KM, Chensue SW, Liu C, Chaudhary MN, Fisher J, Lane TE, Cooke KR. Critical role for CCR1:CCL5 (RANTES) receptor ligand interactions in modulating allogeneic T cell responses following bone marrow transplantation. American Society of Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research (BMT Tandem) Annual Meeting, Abstract Poster Session, Honolulu, HI, February 2006. Biol Blood Marrow Transplant 2006, 12(2):59, February 2006.

10. Levine JE, Kitko C, Goyal R, Ferrell R, Braun T, Mullighan C, Hanauer D, Choi S, Paczesny S, Mineishi S, Cooke KP, Jones D, Whitfield J, Yanik G, Ferrara JLM. An integrated genetic-protein analysis of the TNF-family pathway predicts for GVHD. BMT Tandem Annual Meeting, Abstract Oral Session, Denver, CO, February 2007. Biol Blood Marrow Transplant 13(2):13-14, February 2007.

11. Kitko C, Paczesny S, Yanik G, Braun T, Jones D, Whitfield J, Choi S, Hutchinson R, Ferrara J, Levine JE. Changes in TNFR1 ratios in the first week post-myeloablative allogeneic BMT correlate with GVHD, TRM and OS in children. BMT Tandem Annual Meeting, Abstract Oral Session, Denver, CO, February 2007. Biol Blood Marrow Transplant 13(2):3-4, February 2007.

12. Deurloo DT, Chaudhary MN, Olkiewicz KM, Silva IA, Choi SW, Liu C, Collins TL, Sullivan TJ, Cooke KR. A small molecular weight antagonist of CXCR3 reduces the severity of experimental idiopathic pneumonia syndrome and improves survival following allogeneic stem cell transplantation. BMT Tandem Annual Meeting, Abstract Poster Session, Denver, CO, February 2007. Biol Blood Marrow Transplant 13(2):105, February 2007.

13. Paczesny S, Choi S, Braun T, Kitko C, Krijanovski O, Clouthier S, Weyand A, Bickley D, Jones D, Whitfield J, Levine JE, Ferrara JL. A four protein plasma fingerprint of acute graft versus host disease (GVHD) predicts long-term survival. American Society of Hematology Annual Meeting, Abstract Oral Session, Atlanta, GA, December 2007. Blood 110:38, November 2007.

14. Kato K, Krijanovski O, Khaled Y, Peres E, Reddy P, Choi S, Kitko C, Yanik G, Levine J, Ferrara J, Mineishi S. Allogeneic hematopoietic stem cell transplantation has curative potential for chemorefractory non-hodgkin lymphoma. BMT Tandem Annual Meeting, Abstract Poster Session, San Diego, CA, February 2008. Biol Blood Marrow Transplant 14(2):63-64, February 2008.

15. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JLM. Addition of etanercept to methylprednisolone as initial therapy for acute GVHD results in high response rates and improved survival. BMT Tandem Annual Meeting, Abstract Oral Session, San Diego, CA, Abstract #29. Biol Blood Marrow Transplant 14(2):13, February 2008.

16. Shaffer-Hartman J, Christensen J, Akcasu N, Brescoll J, Teitelbaum D, Lewis I, McNair MJ, Kovacevich D, Neusius, O'Donnell L, Blackwood A, Niedner M, Choi SW. Pediatric Oncology/Bone Marrow Transplant (PHO/BMT) Catheter-Associated Blood Stream Infection (CA-BSI) reduction project: A multi-disciplinary team approach. 19th Annual Pediatric Research Symposium, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, November 2008.

17. Bower K, Choi S, Hanauer D, Levine J, Yanik G, Kitko C. Pericardial and pleural effusions following allogeneic stem cell transplant are associated with decreased overall survival. 19th Annual Pediatric Research Symposium, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, November 2008.

18. Hanauer DA, Choi SW, Beasely RW, Duck MG, Hirschl RB, Blayney DW. Implementation of Computerized Provider Order Entry (CPOE) does not impact provider work time in an inpatient malignant hematology service. 19th Annual Pediatric Research Symposium, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, November 2008.

19. Maslak J, Kaul D, Connelly J, Mineishi S, Levine J, Peres E, Kitko C, Choi S, Khaled Y, Krijanovski O, DiGiandomenico S, White E, Braun T, Reddy P, Pawarode A, Ferrara J, Yanik G. Bronchoscopic evaluation of pulmonary complications in patients undergoing reduced-intensity versus full-intensity transplants. American Society of Hematology Annual Meeting, Abstract Poster Session, San Francisco, CA, December 2008. Blood 112:2163, November 2008.

20. Paczesny S, Levine JE, Hogan J, Crawford J, Braun T, Wang H, Faca V, Zhang Q, Pitteri S, Chin A, Choi S, Kitko C, Krijanovski OI, Reddy P, Mineishi S, Whitfield J, Jones D, Hanash S, Ferrara JLM. Elafin is a biomarker of graft versus host disease of the skin. American Society of Hematology Annual Meeting, Abstract Oral Session, San Francisco, CA, December 2008. Blood 112:716, November 2008.

21. Mineishi S, Magenau J, Pawarode A, Buck T, Jones D, Kato K, Frame D, Kujawski L, Erba HP, Khaled Y, Peres EM, Krijanovski OI, Reddy P, Kitko C, Choi S, Yanik GA, Braun T, Ferrara JLM, Levine JE. Myeloablative conditioning with Clofarabine and Busulfan x 4 (CloBu4) is well tolerated, facilitates secure engraftment, and exhibits significant anti-tumor activity against non-remission hematological malignancies including AML. American Society of Hematology Annual Meeting, Abstract Poster Session, San Francisco, CA, December 2008. Blood 112:2150, November 2008.

22. Paczesny S, Levine JE, Hogan J, Crawford J, Braun TM, Wang H, Faca V, Zhang Q, Pitteri S, Chin A, Choi SW, Kitko CL, Krijanovski OI, Reddy P, Mineishi S, Whitfield J, Jones D, Hanash SM, Ferrara JLM. Elafin is a biomarker of graft versus host disease of the skin. BMT Tandem Annual Meeting, Abstract Oral Session, Tampa, FL. Biol Blood Marrow Transplant 15(2):13-14, February 2009.

23. Magenau J, Pawarode A, Buck T, Jones D, Kato K, Frame D, Kujawski L, Erba HP, Khaled Y, Peres EM, Krijanovski OI, Reddy P, Kitko C, Choi S, Yanik G, Braun T, Ferrara JLM, Levine JE, Mineishi S. Conditioning with Clofarabine and Busulfan x 4 (CloBu4) for non-remission hematologic malignancies including AML is well tolerated, facilitates secure engraftment, and exhibits significant anti-tumor activity. BMT Tandem Annual Meeting, Abstract Poster Session, Tampa, FL. Biol Blood Marrow Transplant 15(2):104, February 2009.

24. Krijanovski O, Krijanovski Y, Khaled Y, Cummings T, Braun T, Reddy P, Peres E, Mineishi S, Kitko C, Choi S, Yanik G, Pawarode A, Paczesny S, Levine JE. Rapid immunosuppression taper following reduced intensity HCT from related donor is tolerable but does not improve outcomes of advanced hematologic malignancies. BMT Tandem Annual Meeting, Abstract Oral Session, Tampa, FL, February 2009. Biol Blood Marrow Transplant 15(2):6-7, February 2009.

25. Kitko CL, Mineishi S, Braun T, Choi SW, Jones D, Harris A, Khaled Y, Krijanovski O, Paczesny S, Peres E, Yanik G, Whitfield J, Ferrara JL, Levine JE. Day 7 TNFR1 levels following reduced intensity allogeneic hematopoietic stem cell transplant (HCT) predict for acute GVHD. BMT Tandem Annual Meeting, Abstract Poster Session, Tampa, FL, February 2009. Biol Blood Marrow Transplant 15(2):129, February 2009.

26. Choi S, Stiff P, Braun T, Ferrara JLM, Cooke KR, Khaled Y, Kitko C, Lay-Luskin J, Mineishi S, Nickoloff B, Paczesny S, Pawarode A, Whitfield J, Peres EM, Reddy P, Richardson J, Rodriguez T, Smith SE, Yanik GA, Levine JE. Standard GVHD prophylaxis augmented with TNF-inhibition in alternative donor HCT: lower TNFR1 levels correlate with better outcomes. American Society of Hematology Annual Meeting, Abstract Oral Session, New Orleans, LA, December 2009. Blood 114:43, November 2009.

27. Magenau JM, Qin X, Tawara I, Rogers CE, Schlough M, Bickley D, Jang PS, Braun TM, Lowler K, Jones DM, Choi SW, Mineishi S, Levine JE, Ferrara JLM, Paczesny S. Frequency of CD4+CD25hiFOXP3+ regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host disease. American Society of Hematology Annual Meeting, Abstract Oral Session, New Orleans, LA, December 2009. Blood 114:514, November 2009.

28. Khaled Y, Choi S, Hanauer DA, Reddy P. Nephrotic syndrome after allogeneic hematopoietic cell transplantation: incidence and outcomes. American Society of Hematology Annual Meeting, Abstract Poster Session, New Orleans, LA, December 2009. Blood 114:3324, November 2009.

29. Choi S, Stiff P, Braun T, Ferrara JLM, Cooke KR, Khaled Y, Kitko C, Lay-Luskin J, Mineishi S, Nickoloff B, Paczesny S, Pawarode A, Whitfield J, Peres EM, Reddy P, Richardson J, Rodriguez T, Smith SE, Yanik GA, Levine JE. TNF-inhibition with etanercept for GVHD prevention in alternative donor HCT: lower TNFR1 levels correlate with better outcomes. BMT Tandem Annual Meeting, Abstract Oral Session, Orlando, FL, February 2010. Biol Blood Marrow Transplant 16(2):S157-S158, February 2010.

30. Harris AC, Magenau J, Braun T, Kitko CL, Choi SW, Ferrara JLM, Mineishi S, Pawarode A, Peres E, Reddy P, Yanik G, Levine JE. Extramedullary relapse in acute leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcomes. BMT Tandem Annual Meeting, Abstract Oral Session, Orlando, FL, February 2010. Biol Blood Marrow Transplant 16(2):S177-S178, February 2010.

31. Khaled YA, Choi SW, Hanauer DA, Levine JE, Peres E, Kitko C, Reddy P. Nephrotic syndrome after allogeneic hematopoietic cell transplantation: incidence and outcomes. BMT Tandem Annual Meeting, Abstract Poster Session, Orlando, FL, February 2010. Biol Blood Marrow Transplant 16(2):S226, February 2010.

32. Hanauer DA, Zheng K, Choi SW, Beasley R, Schumacher J, Duck M, Blayney DW. Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service. American Society of Clinical Oncology (ASCO) Annual Meeting, Abstract Poster Session, Chicago, IL, June 2010. J Clin Oncol 28:7s, May 2010.

33. Paczesny S, Braun T, Vander Lugt M, Harris A, Fiema B, Hernandez J, Choi S, Kitko C, Magenau J, Yanik G, Peres EM, Pawarode A, Mineishi S, Whitfield J, Jones D, Couriel D, Reddy P, Hanash S, Ferrara JLM, Levine JE. Three biomarker panel at day 7 and 14 can predict development of grade 2-4 acute GVHD. American Society of Hematology Annual Meeting, Abstract Oral Session, Orlando, FL, December 2010. Blood 116:675, November 2010.

34. Mineishi S, Magenau J, Tobai H, Pawarode A, Peres EM, Reddy P, Kitko C, Choi S, Erba HP, Kujawski L, Yanik G, Ferrara J, Levine JE. Allogeneic hematopoietic stem cell transplantation with clofarabine/busulfan x4 (CloBu4) conditioning exhibits significant anti-tumor activity in non-remission hematologic malignancies, especially in AML. American Society of Hematology Annual Meeting, Abstract Oral Session, Orlando, FL, December 2010. Blood 116:35, November 2010.

35. Paczesny, S, Braun T, Vander Lugt M, Harris A, Fiema B, Hernandez J, Choi SW, Kitko C, Magenau J, Yanik G, Peres EM, Pawarode S, Mineishi S, Whitfield J, Jones D, Couriel D, Pavan R, Hanash S, Ferrara JLM, Levine JE. A three biomarker panel at days 7 and 14 can predict development of grade 2-4 acute GVHD. BMT Tandem Annual Meeting, Abstract Oral Session, Honolulu, HI, February 2011. Biol Blood Marrow Transplant 17(2):S167, February 2011.

36. Harris AC, Ferrara JLM, Levine JE, Braun T, Hogan J, Crawford J, Pitteri S, Wang H, Chin A, Zhang Q, Granger J, Vander Lugt M, Byersdorfer C, Magenau J, Gomez A, Choi S, Kitko C, Yanik G, Peres E, Pawarode A, Mineishi S, Reddy P, Couriel DR, Hanash S, Paczesny S. Reg3α is a biomarker of graft versush host disease of the gastrointestinal tract. BMT Tandem Annual Meeting, Abstract Oral Session, Honolulu, HI, February 2011. Biol Blood Marrow Transplant 17(2):S163-S164, February 2011.

37. Vander Lugt MT, Braun T, Ferrara JLM, Sanash S, Levine JE, Wang CH, Zhang Q, Chin A, Harris AC, Choi SW, Couriel D, Reddy P, Paczesny S. Plasma concentration of ST2, the IL33 receptor, at initiation of graft versus host disease therapy predicts day 28 response and day 180 survival post-treatment. American Society of Hematology Annual Meeting, Oral Session, San Diego, CA, December 2011. Blood 118: 152, November 2011.

38. Harris AC, Ferrara JLM, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E, Landfried K, Akashi K, Vander Lugt MT, Reddy P, Chin A, Zhang A, Hanash S, Paczesny S. A novel grading system of lower gastrointestinal acute GVHD at disease onset predicts response to therapy and non-relapse mortality. American Society of Hematology Annual Meeting, Oral Session, San Diego, CA, December 2011. Blood 118: 153, November 2011.

39. Frame, Martell A, Markstrom D, Choi S, Couriel D. Levetiracetam is efficacious for prevention of busulfan induced seizures. BMT Tandem Annual Meeting, Abstract Oral Session, San Diego, CA, February 2012. Biol Blood Marrow Transplant 18(2):S380, February 2012.

40. Choi SW, DiPersio JF, Braun TM, Hou G, Stockerl-Goldstein K, Tawara I, Levine JE, Sun Y, Couriel DR, Krijanovski OI, Chang L, Magenau JM, Pawarode A, Kitko C, Paczesny S, Peres EM, Mineishi S, Yanik GA, Lehmann M, Dinarello CA, Ferrara JLM, Reddy P. Targeting histone deacetylases as a new strategy for graft versus host disease prevention. American Society of Hematology Annual Meeting, Abstract Oral Session, Atlanta, GA, December 2012. Blood 120: 740, November 2012.

41. Vander Lugt M, Braun TM, Sanash S, Ferrara JLM, Ritz J, Ho VT, Antin JH, Zhang Q, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Paczesny S. Plasma ST2 concentrations predict development of acute GVHD and non-relapse mortality. American Society of Hematology Annual Meeting, Abstract Oral Session, Atlanta, GA, December 2012. Blood 120: 466, November 2012.

42. Cutler C, Logan BR, Nakamura R, Johnston L, Choi SW, Porter DL, Hogan WJ, Pasquini MC, MacMillan ML, Wingard JR, Waller EK, Grup SA, McCarthy PL, Wu J, Hu Z, Carter SL, Horowitz MM, Antin JH. Tacrolimus/sirolimus vs tacrolimus/methotrexate for graft-vs.-host disease prophylaxis after HLA-matched, related donor hematopoietic stem cell transplantation: results of Blood and marrow Transplant Clinical Trials Network Trial 0402. American Society of Hematology Annual Meeting, Abstract Oral Session, Atlanta, GA, December 2012. Blood 120: 739, November 2012.

43. Yanik GA, Magenau JM, Mineishi S, Pawarode A, Alangaden K, Peres EM, Goldstein S, Levine JE, Choi S, Kitko CL, Talpaz M, Couriel D. Unrelated donor transplants for older AML patients using a low dose TBI containing regimen are as efficacious as related donor transplants, and exhibit favorable outcomes for intermediate risk disease. American Society of Hematology Annual Meeting, Abstract Poster Session, Atlanta, GA, December 2012. Blood 120: 3119, November 2012.

44. Kitko CL, Saliba RM, Paczesny S, Kennel M, Choi SW, Reddy P, Levine JE, Couriel DR. Risk factors for non-relapse mortality in chronic graft versus host disease: predicting outcomes at disease onset. American Society of Hematology Annual Meeting, Abstract Poster Session, Atlanta, GA, December 2012. Blood 120:1941, November 2012.

45. Choi SW, Stockerl-Goldstein K, James F, Levine J, Krijanovski O, Braun Tom, Mineishi S, Couriel D, Paczesny S, Kitko C, Magenau M, Yanik G, Peres E, Pawarode A, Lehmann M, DiPersio J, Reddy P. Targeting histone deacetylases as a new strategy for graft versus host disease prevention. Central Society for Clinical and Translational Research Annual Meeting. Abstract Poster Session, Chicago, IL, April 2012. K Award Grant recipient.

46. Choi SW, Hou G, Beumer JH, Tawara I, Sun Y, Braun T, Chang L, Dinarello C, Ferrara JLM, DiPersio JF, Reddy P. Targeting deacetylases as a novel strategy for prevention of acute GVHD. BMT Tandem Annual Meeting, ASBMT Best Abstract Award for Basic Science, Salt Lake City, UT, February 2013. Biol Blood Marrow Transplant 19(2): S109-S110, February 2013.

47. Magenau J, Pawarode A, Couriel DR, Yanik G, Mineishi S, Braun T, Reddy P, Ferrara JLM, Frame D, Choi SW, Harris AC, Kitko CL, Connelly JA, Levine J, Goldstein SC. Impact of dose intensification of FluBu2 to FluBu4 on transplant related mortality, relapse, and survival after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in remission. BMT Tandem Annual Meeting, Abstract Poster Session, Salt Lake City, UT, February 2013. Biol Blood Marrow Transplant 19(2): S226, February 2013.

48. Yanik G, Magenau J, Goldstein SC, Pawarode A, Talpaz M, Levine J, Choi S, Kitko CL, Couriel DR. A prospective study of allogeneic transplant for older patients with acute myelogenous leukemia (AML) indicates that unrelated donor transplants are as efficacious as related donor, with favorable outcomes for intermediate risk disease. BMT Tandem Annual Meeting, Abstract Poster Session, Salt Lake City, UT. Biol Blood Marrow Transplant 19(2): S232, February 2013.

49. Pawarode A, Mineishi S, Braun T, Ferrara JLM, Magenau J, Peres E, Yanik G, Reddy P, Levine JE, Choi SW, Kitko CL, Harris AC, Connelly JA, Goldstein SC, Couriel DR. Phase 2 study of allogeneic hematopoietic cell transplant (HCT) following intermediate-intensity fludarabine and busulfan x 4 (FluBu4) conditioning for high-risk or advanced multiple myeloma. BMT Annual Tandem Meeting, Abstract Poster Session, Salt Lake City, UT. Biol Blood Marrow Transplant 19(2): S238, February 2013.

50. Vander Lugt M, Braun T, Ferrara JLM, Hanash S, Levine JE, Sang CH, Zhang Q, Zhang Q, Chin A, Harris A, Choi SW, Couriel D, Reddy P, Paczesny S. Plasma concentration of suppressor of tumorigenicity 2 (ST2), the IL33 receptor, at initiation of graft versus host disease therapy predicts day 28 response and day 180 survival post-treatment. BMT Annual Tandem Meeting, Abstract Oral Session, Salt Lake City, UT. Biol Blood Marrow Transplant 19(2): S201-S202, February 2013.

51. Vander Lugt M, Braun T, Hanash S, Ferrara JLM, Ritz J, Ho VT, Antin J, Zhang A, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel DR, Reddy P, Paczesny S. Plasma ST2 concentrations predict acute GVHD development and non-relapse mortality. BMT Annual Tandem Meeting, Abstract Oral Session, Salt Lake City, UT. Biol Blood Marrow Transplant 19(2): S142-S143, February 2013.

52. Harris AC, Ferrara JLM, Braun T, Couriel DR, Choi S, Kitko CL, Goldstein SC, Magenau J, Paczesny S, Pawarode A, Reddy P, Yanik G, Taylor A, Connelly JA, Byersdorfer CA, Levine JE. A combination of clinical characteristics and day 7 biomarker concentrations predicts graft-versus-host disease following hematopoietic cell transplantation from related donors. BMT Annual Tandem Meeting, Abstract Oral Session, Salt Lake City, UT. Biol Blood Marrow Transplant 19(2): S138, February 2013.

53. Kitko CL, Saliba R, Choi SW, Reddy P, Goldstein SC, Magenau J, Pawarode, Kennel M, Levine JE, White E, Couriel DR. Biomarkers of extracellular matrix remodeling in chronic GVHD. BMT Annual Tandem Meeting, Abstract Poster Session, Salt Lake City, UT. Biol Blood Marrow Transplant 19(2): S332, February 2013.

54. Kitko CL, Saliba R, Paczesny P, Kennel, Choi S, Reddy P, Levine J, Couriel DR. Non-relapse mortality in chronic graft versus host disease: Risk factors at onset and response to treatment. BMT Annual Tandem Meeting, Abstract Poster Session, Grapevine, TX. Biol Blood Marrow Transplant 19(2): S332, February 2013.

55. Abedin S, Peres E, Levine J, Pawarode A, Choi SW, Couriel DR. Double umbilical cord blood transplantation after novel myeloablative conditioning using FluBu4TLI. BMT Annual Tandem Meeting, Abstract Poster Session, Grapevine, TX. Biol Blood Marrow Transplant 20(2): S211, February 2014.

56. Pawarode A, Braun T, Magenau J, Choi SW, Kitko CL, Yanik G, Goldstein SC, Couriel DR. Allogeneic hematopoietic cell transplant (Allo-HCT) for advanced diffuse large B-Cell Non-Hodkin's Lymphoma: The University of Michigan Experience. BMT Annual Tandem Meeting, Abstract Poster Session, Grapevine, TX. Biol Blood Marrow Transplant 20(2): S76, February 2014.

57. Gatza E, Hou G, Song Y, Oravecz-Wilson K, Sun Y, Choi SW, Reddy P. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in human. A. Alfred Taubman Medical Research Symposium, Abstract Poster Session, Ann Arbor, MI, October 2014.

58. Gleimer M, Li Y, Chang L, Paczesny, Hanauer DA, Frame DG, Byersdorfer, Reddy PR, Braun TM, Choi SW. Body mass index predicts outcomes of allogeneic hematopoietic cell transplantation. Annual Pediatric Research Symposium, Department of Pediatrics and Communicable Diseases, University of Michigan, Abstract Poster Session, Ann Arbor, MI, October 2014. American Society of Hematology Annual Meeting, Abstract Poster Session, San Francisco, CA. Blood 124: 2558, December 2014.

59. Toubi T, Rossi C, Oravecz-Wilson K, Liu C, Matthewson N, Sun Y, Wu J, Zheng P, Liu Y, Choi SW, Reddy P. Siglec-G expression on donor T cells controls severity of GVHD. BMT Annual Tandem Meeting, Abstract Oral Session, San Diego, CA. Biol Blood Marrow Transplant, February 2015.

60. Harris AC, Braun T, Byersdorfer C, Choi SW, Connelly JA, Kitko CL, Yanik G, Levine J. Fludarabine combined with myeloablative busulfan (FluBu4) result in reliable engraftment and low transplant-related mortality in pediatric patients. BMT Annual Tandem Meeting, Abstract Poster Session, San Diego, CA. Biol Blood Marrow Transplant, February 2015.

61. Kitko CL, Braun T, Choi SW, Yanik G, Pawarode A, Magenau J, Taylor A, Ferrara JLM, Couriel DR, Levine J. Phase 2 clinical trial of etanercept plus extracorporeal photopheresis GVHD prophylaxis following unrelated donor reduced intensity transplant. BMT Annual Tandem Meeting, Abstract Poster Session, San Diego, CA. Biol Blood Marrow Transplant, February 2015.

62. Bouma S, Peterson M, Gatza E, Klein D, Bauman M, Praduman J, Choi SW. Nutritional status and weakness in pediatric hematopoietic cell transplantation survivors. Cancer Survivorship Conference, Abstract Poster Session, Washington, D.C. Cancer Survivorship Research Conference: Innovation in a Rapidly Changing Landscape, June 2016.

63. Runaas L, Bischoff E, Hoodin F, Kentor R, Ostarello L, Seyedsalehi S, Hanauer DA, Choi SW. A novel health informatics tool to improve caregiver activation: Findings from pediatric BMT in a Hospital-Based Setting. American Society of Hematology, Abstract Session, San Diego, CA, December 2016.

64. Cuvelier G, Nemecek E, Wahlstrom JT, Harris A, Pulsipher MA, Lewis V, Bittencourt H, Choi SW, Kitko CL, Caywood E, Bhatia M, Kasow KA, Jacobsohn D, Petrovic A, Kheradpour A, Chaudhury S, Chewning J, Schechter T, Abikoff C, Coulter D, Joyce M, Savasan S, Pawlowska A, Megason G, Mitchell D, Cheerva A, Halevy A, Schultz KR. Challenges with Diagnosing Pulmnary Chronic GVHD in Children According to the 2014 National Institutes of health Consensus Criteria: Analysis of the Applied Biomarkers of Late Effects (ABLE) / Pediatric Blood and Marrow Transplant Consortium (PBMTC) 1202 Study. BMT Annual Tandem Meeting, abstract submitted (February 2017).

65. Runaas L, Hoodin F, Kentor R, Seyedsalehi S, Ostarello L, Bischoff E, Byrd M, Brookshire K, Warfield C, McDiarmid L, Fauer A, Munaco A, Sankaran R, Gupta R, Hoang T, Magenau J, Hanauer DA, Choi SW. User-centered design and development of a personalized mobile health application for adult HCT patients in the inpatient setting. BMT Annual Tandem Meeting, abstract submitted (February 2017).